<DOC>
	<DOC>NCT02867839</DOC>
	<brief_summary>The purpose of the study is to evaluate the efficacy and safety of S-1 plus Oxaliplatin versus S-1 only as adjuvant chemotherapy after curative distal gastrectomy in patients with locally advanced gastric cancer.</brief_summary>
	<brief_title>Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric Cancer</brief_title>
	<detailed_description>The study is a multi-central, controlled, randomized Phase III trial. The protocol has been approved by the Ethics Committee of Beijing Cancer Hospital. The primary endpoint is the 3-year progression-free survival (PFS) rate. The secondary endpoints are the overall survival (OS) and safety.</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>sign written informed consent form age ≥ 18 years, ≤69 years ECOG status: 0~2 pathologically confirmed gastric cancer at stage II or IIIA (AJCC 7th version) negative peritoneal cytology underwent curative distal gastrectomy with D2 lymph node dissection no prior antitumor treatment is allowed, including chemotherapy, radiotherapy, immune therapy or target therapy adequate organ function as defined below: Hematologic ANC ≥ 2*109/L, Platelets ≥ 100*109/L, AST and ALT ≤ 2.5×ULN, TBIL ≤ 1.5×ULN. be enrolled in other clinical trials underwent prior antitumor treatment allergic reaction to S1 or oxaliplatin abnormal GI tract function female in pregnancy or lactation, or refuse to receive Contraception measures during chemotherapy other situation to be judged not adaptive to the study by investigators</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Gastric cancer</keyword>
	<keyword>Adjuvant chemotherapy</keyword>
	<keyword>S1</keyword>
	<keyword>Oxaliplatin</keyword>
</DOC>